Chronic Lymphocytic Leukemia News Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
TG Therapeutics has decided to take Ukoniq (umbralisib) off the market and withdraw pending applications for the drug.
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
An initial review of data from the phase 3 UNITY trial in CLL patients showed the combination of Ukoniq and ublituximab was associated with increased risk of death compared with the control arm.
Night shift work may increase the risk of developing chronic lymphocytic leukemia but not other types of lymphoma.
A novel prognostic index can identify patients with chronic lymphocytic leukemia who are at low risk of requiring treatment, according to researchers.
The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
Despite an inferior rate of seroconversion, lymphoma patients treated with anti-CD20 therapy did mount T-cell responses.
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Researchers presented updated findings from the GLOW trial.
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
Load More